Primary series COVID-19 vaccine effectiveness among healthcare workers in Albania, February-December 2021.
Primary series COVID-19 vaccine effectiveness among healthcare workers in Albania, February-December 2021.
复制标题
DOI：
10.1016/j.ijregi.2023.04.009
复制
发表时间：
2023-09
期刊：
影响因子：
--
通讯作者：
Bino, Silvia
中科院分区：
文献类型：
--
作者：
Rubin-Smith, Julia E.;Castro, Madelyn Yiseth Rojas;Preza, Iria;Hasibra, Iris;Sulo, Jonilda;Fico, Albana;Daja, Rovena;Vasili, Adela;Kota, Majlinda;Schmid, Alexis;Sridhar, Shela;Guseinova, Alina;Boshevska, Golubinka;Bejtja, Gazmend;Muehlemann, Barbara;Drosten, Christian;Jorgensen, Pernille;Pebody, Richard;Kissling, Esther;Lafond, Kathryn E.;Katz, Mark A.;Bino, Silvia
医护人员经历了冠状病毒病的高发病率和死亡率2019年疫苗有效性在那些有或没有感染过严重急性呼吸综合征冠状病毒-2的人中为中等。混合免疫--感染后接种疫苗的保护作用--很强。无论以前的感染状况如何，接种疫苗在人群中都是有益的。医护人员经历了2019年冠状病毒病的高发病率和死亡率(新冠肺炎)。2021年2月19日至12月14日，在阿尔巴尼亚的三家医院进行了一项前瞻性队列研究。所有参与者在登记时都接受了聚合酶链式反应(PCR)和血清学检测，在整个过程中都进行了定期的血清学检测，并在出现症状时进行了PCR检测。评估对新冠肺炎和所有严重急性呼吸综合征冠状病毒-2感染(有症状或无症状)的疫苗效力(VE)。VE的估算采用COX回归模型，接种状况为时变变量。总共有1504名医务工作者参加了这项研究；70%的人有SARS-CoV-2感染的证据。对新冠肺炎的VE为65.1%[95%可信区间为37.7~80.5]，无SARS-CoV感染史的VE为58.2%(95%CI为15.7~79.3)，有SARS-CoV感染史的VE为73.6%(95%CI为24.3~90.8)。单纯BNT162b2的VE为69.5%(95%CI为44.5-83.2)。在Delta变异占优势的时期，VE为67.1%(95%可信区间为38.3-82.5)。在整个研究期间，VE对SARS-CoV-2感染的抵抗率为36.9%(95%CI为15.8~52.7)。这项研究发现，在阿尔巴尼亚的医护人员中，中度初级系列VE对新冠肺炎不利。这些结果支持在阿尔巴尼亚继续推广接种新冠肺炎疫苗，并突出了在既往感染水平较高的人群中接种疫苗的好处。
Healthcare workers experienced high rates of morbidity and mortality from coronavirus disease 2019 Vaccine effectiveness is moderate in those with or without prior infection with severe acute respiratory syndrome coronavirus-2. Hybrid immunity – the protective effect of infection followed by vaccination – was strong. Vaccination is beneficial in populations regardless of prior infection status. Healthcare workers have experienced high rates of morbidity and mortality from coronavirus disease 2019 (COVID-19). A prospective cohort study was conducted in three Albanian hospitals between 19 February and 14 December 2021. All participants underwent polymerase chain reaction (PCR) and serological testing at enrolment, regular serology throughout, and PCR testing when symptomatic. Vaccine effectiveness (VE) against COVID-19 and against all severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections (symptomatic or asymptomatic) was estimated. VE was estimated using a Cox regression model, with vaccination status as a time-varying variable. In total, 1504 HCWs were enrolled in this study; 70% had evidence of prior SARS-CoV-2 infection. VE was 65.1% [95% confidence interval (CI) 37.7–80.5] against COVID-19, 58.2% (95% CI 15.7–79.3) among participants without prior SARS-CoV-2 infection, and 73.6% (95% CI 24.3–90.8) among participants with prior SARS-CoV-2 infection. For BNT162b2 alone, VE was 69.5% (95% CI 44.5–83.2). During the period when the Delta variant was predominant, VE was 67.1% (95% CI 38.3–82.5). VE against SARS-CoV-2 infection for the full study period was 36.9% (95% CI 15.8–52.7). This study found moderate primary series VE against COVID-19 among healthcare workers in Albania. These results support the continued promotion of COVID-19 vaccination in Albania, and highlight the benefits of vaccination in populations with high levels of prior infection.
登录
查看更多内容
DOI：
10.2807/1560-7917.es.2021.26.47.2101021
发表时间：
2021-11
期刊：
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
影响因子：
--
作者：
Meslé MM;Brown J;Mook P;Hagan J;Pastore R;Bundle N;Spiteri G;Ravasi G;Nicolay N;Andrews N;Dykhanovska T;Mossong J;Sadkowska-Todys M;Nikiforova R;Riccardo F;Meijerink H;Mazagatos C;Kyncl J;McMenamin J;Melillo T;Kaoustou S;Lévy-Bruhl D;Haarhuis F;Rich R;Kall M;Nitzan D;Smallwood C;Pebody RG
通讯作者：
Pebody RG
既往 SARS-CoV-2 感染和混合免疫对 omicron 变异和严重疾病的保护有效性：系统评价和荟萃回归。
影响因子：
56.3
作者：
Bobrovitz, Niklas;Ware, Harriet;Ma, Xiaomeng;Li, Zihan;Hosseini, Reza;Cao, Christian;Selemon, Anabel;Whelan, Mairead;Premji, Zahra;Issa, Hanane;Cheng, Brianna;Abu Raddad, Laith J.;Buckeridge, David L.;Van Kerkhove, Maria D.;Piechotta, Vanessa;Higdon, Melissa M.;Wilder-Smith, Annelies;Bergeri, Isabel;Feikin, Daniel R.;Arora, Rahul K.;Patel, Minal K.;Subissi, Lorenzo
通讯作者：
Subissi, Lorenzo
影响因子：
13.8
作者：
Vilches TN;Moghadas SM;Sah P;Fitzpatrick MC;Shoukat A;Pandey A;Galvani AP
通讯作者：
Galvani AP
影响因子：
2.9
作者：
Sridhar S;Fico A;Preza I;Hatibi I;Sulo J;Kissling E;Daja R;Ibrahim R;Lemos D;Rubin-Smith J;Schmid A;Vasili A;Valenciano M;Jorgensen P;Pebody R;Lafond KE;Katz MA;Bino S
通讯作者：
Bino S
DOI：
10.1016/s2666-5247(20)30120-8
发表时间：
2020-11
期刊：
The Lancet. Microbe
影响因子：
--
作者：
Wajnberg A;Mansour M;Leven E;Bouvier NM;Patel G;Firpo-Betancourt A;Mendu R;Jhang J;Arinsburg S;Gitman M;Houldsworth J;Sordillo E;Paniz-Mondolfi A;Baine I;Simon V;Aberg J;Krammer F;Reich D;Cordon-Cardo C
通讯作者：
Cordon-Cardo C